Carmignac Gestion increased its stake in Chemocentryx Inc (CCXI) by 26.83% based on its latest 2018Q3 regulatory filing with the SEC. Carmignac Gestion bought 275,273 shares as the company’s stock declined 9.75% with the market. The institutional investor held 1.30 million shares of the health care company at the end of 2018Q3, valued at $16.45 million, up from 1.03 million at the end of the previous reported quarter. Carmignac Gestion who had been investing in Chemocentryx Inc for a number of months, seems to be bullish on the $505.76 million market cap company. The stock decreased 0.89% or $0.09 during the last trading session, reaching $10.01. About 59,164 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since December 21, 2017 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En
Ycg Llc decreased its stake in Unilever N V (UN) by 12.11% based on its latest 2018Q3 regulatory filing with the SEC. Ycg Llc sold 60,616 shares as the company’s stock declined 1.18% with the market. The institutional investor held 439,748 shares of the package goods and cosmetics company at the end of 2018Q3, valued at $24.43M, down from 500,364 at the end of the previous reported quarter. Ycg Llc who had been investing in Unilever N V for a number of months, seems to be less bullish one the $145.56B market cap company. The stock decreased 0.02% or $0.01 during the last trading session, reaching $54.2. About 926,623 shares traded. Unilever N.V. (NYSE:UN) has declined 3.66% since December 21, 2017 and is downtrending. It has underperformed by 3.66% the S&P500. Some Historical UN News: 20/03/2018 – Unilever Priced a Quadruple-Tranche $2.1B Bond; 04/04/2018 – The Drum: Unilever agency team lead Soche Picard joins retail shop Arc to North American CEO; 03/05/2018 – UNILEVER’S PHILIPPINE SALES HEALTHY IN 1Q: CHAIRMAN SAYS AT ADB; 15/03/2018 – Unilever Will Continue to Be Listed in London, Amsterdam and NY; 14/03/2018 – Unilever poised to choose Rotterdam over London; 16/03/2018 – Unilever has chosen to protect itself from modern capitalism; 20/04/2018 – UNILEVER NV UNc.AS : INDEPENDENT RESEARCH RAISES TARGET PRICE TO EUR 49.00 FROM EUR 47.00; RATING HOLD; 28/03/2018 – Unilever: Closure Puts 113 Jobs at Risk of Redundancy; 06/05/2018 – Unilever credit initiative aims to drive Africa revenues; 14/05/2018 – Hindustan Unilever January-March Net Profit INR13.51 Billion
Ycg Llc, which manages about $279.00M and $503.20M US Long portfolio, upped its stake in Cbre Group Inc (NYSE:CBG) by 102,957 shares to 590,821 shares, valued at $26.06 million in 2018Q3, according to the filing. It also increased its holding in Facebook Inc (NASDAQ:FB) by 53,064 shares in the quarter, for a total of 85,837 shares, and has risen its stake in Schwab Charles Corp New (NYSE:SCHW).
Among 11 analysts covering Unilever NV (NYSE:UN), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. Unilever NV had 13 analyst reports since September 25, 2015 according to SRatingsIntel. The rating was downgraded by RBC Capital Markets on Friday, July 22 to “Sector Perform”. The firm has “Underperform” rating by RBC Capital Markets given on Thursday, August 10. On Tuesday, January 12 the stock rating was upgraded by JP Morgan to “Overweight”. The rating was upgraded by Credit Suisse to “Neutral” on Tuesday, December 8. Jefferies upgraded the shares of UN in report on Tuesday, December 13 to “Buy” rating. Citigroup upgraded Unilever N.V. (NYSE:UN) on Wednesday, August 31 to “Buy” rating. Liberum Capital reinitiated the stock with “Hold” rating in Monday, March 27 report. Bernstein initiated the stock with “Outperform” rating in Monday, August 22 report. UBS upgraded the shares of UN in report on Wednesday, March 28 to “Buy” rating. The firm earned “Neutral” rating on Wednesday, December 7 by JP Morgan.
More important recent Unilever N.V. (NYSE:UN) news were published by: Investorplace.com which released: “Donâ€™t Buy the Headlines or Clorox Stock at All Right Now – Investorplace.com” on November 30, 2018, also Seekingalpha.com published article titled: “Glaxo in talks with Unilever to sell Horlicks unit – FT – Seeking Alpha”, Profitconfidential.com published: “AYX Stock: More Double-Digit Upside for This Data Specialist – Profit Confidential” on November 22, 2018. More interesting news about Unilever N.V. (NYSE:UN) was released by: Investorplace.com and their article: “10 Defensive Stocks to Protect Your Portfolio in 2019 – Investorplace.com” with publication date: December 04, 2018.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference – GlobeNewswire” on November 29, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Crude Oil Up 1.5%; Altimmune Shares Plunge – Nasdaq” published on September 28, 2018, Globenewswire.com published: “ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights – GlobeNewswire” on May 09, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “Chemokine Receptor Antagonists: ChemoCentryx Is An Aged Red Wine Ripe For Success – Seeking Alpha” published on March 07, 2018 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018.
Among 8 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. ChemoCentryx had 12 analyst reports since September 3, 2015 according to SRatingsIntel. The company was initiated on Tuesday, February 21 by JMP Securities. The firm has “Neutral” rating given on Tuesday, August 14 by JP Morgan. The firm has “Overweight” rating given on Tuesday, March 13 by JP Morgan. The rating was downgraded by Zacks on Monday, September 21 to “Sell”. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Thursday, August 10 by JMP Securities. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Monday, November 12 by Canaccord Genuity. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Sell” rating by Zacks on Thursday, September 3. On Tuesday, August 8 the stock rating was maintained by Cowen & Co with “Hold”.
Investors sentiment decreased to 0.98 in Q3 2018. Its down 0.61, from 1.59 in 2018Q2. It dived, as 14 investors sold CCXI shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Wasatch Advisors holds 2.39 million shares or 0.35% of its portfolio. Product Ptnrs Ltd Liability stated it has 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Comml Bank Of Montreal Can owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 130,682 shares. Strs Ohio holds 52,400 shares or 0% of its portfolio. 17,811 were reported by Sectoral Asset. Amer Grp reported 14,904 shares stake. Gsa Capital Ltd Liability Partnership accumulated 164,800 shares. Citadel Advisors Ltd holds 50,701 shares or 0% of its portfolio. Vanguard Grp Inc reported 1.33 million shares stake. Rhumbline Advisers holds 21,117 shares. Baker Bros Limited Partnership has invested 0.03% in ChemoCentryx, Inc. (NASDAQ:CCXI). Dekabank Deutsche Girozentrale reported 20,000 shares. Jpmorgan Chase And has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Fosun Intl Ltd has 159,050 shares. Cadence Cap Ltd Liability reported 95,344 shares or 0.07% of all its holdings.
Since June 26, 2018, it had 0 buys, and 7 insider sales for $88.11 million activity. Schall Thomas J. had sold 7,211 shares worth $86,554 on Wednesday, November 7. Cappel Markus J. sold 25,179 shares worth $344,201. $85.85M worth of stock was sold by GLAXOSMITHKLINE PLC on Tuesday, October 16.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.